Among patients with T2DM and CKD treated with RAAS blockade, recent studies have shown that SGLT2 inhibition with canagliflozin may also reduce the risk of hyperkalemia without increasing the risk of hypokalemia [47]. The gene discussed is SLC5A2; the disease is chronic kidney disease.